Want to see RMTG full AI Analyst Report?
Top Page
Regenerative Medical Technology Group
(OTC:RMTG)
Select Model
Select Model
Rating:52Neutral
Price Target:
$0.08
▼(-19.00% Downside)
Action:Reiterated
Date:08/25/26
The score is held back primarily by weak financial performance (large net losses, negative equity, and negative free cash flow), which raises balance-sheet and funding risk. Technicals are comparatively supportive with an uptrend across key moving averages and positive momentum. Valuation remains challenged due to negative earnings, while the recent corporate update is moderately positive on growth but tempered by leverage and financing risk.
Positive Factors
Strong revenue growth and gross margin
Rapid top-line expansion combined with a solid gross margin indicates meaningful customer demand and positive unit economics. If maintained, this revenue base can provide greater operating leverage and support investment in products, education, and clinical activities as the company scales.
Negative Factors
Deep and persistent net losses
Large net losses indicate that overhead, research and development, and other costs still overwhelm the company’s gross profit base. Until earnings improve materially, internal funding capacity remains weak and growth may continue to require external capital or financing support.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth and gross margin
Rapid top-line expansion combined with a solid gross margin indicates meaningful customer demand and positive unit economics. If maintained, this revenue base can provide greater operating leverage and support investment in products, education, and clinical activities as the company scales.
Read all positive factors
Regenerative Medical Technology Group (RMTG) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.10M
Dividend YieldN/A
Average Volume (3M)70.34K
Price to Earnings (P/E)―
Beta (1Y)-1.53
Revenue Growth94.32%
EPS Growth-158.38%
CountryUS
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding13,738,968
10 Day Avg. Volume67,590
30 Day Avg. Volume70,336
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.02
Price to Sales (P/S)0.12
P/FCF Ratio-0.47
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Regenerative Medical Technology Group Business Overview & Revenue Model
Company Description
Regenerative Medical Technology Group Inc. operates in the regenerative medicine industry in the United States and internationally. It provides products, solutions, equipment, services, and training to doctors and their staff in the application of...
Regenerative Medical Technology Group Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
18
Very Negative
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.41M | 5.10M | 4.11M | 2.41M | 1.53M | 437.89K |
| Gross Profit | 5.51M | 2.81M | 2.82M | 1.68M | 876.97K | 150.14K |
| EBITDA | 2.00M | -83.56K | 301.74K | -3.01M | -1.02M | -10.11M |
| Net Income | -9.53M | -7.81M | -5.56M | -9.81M | -5.49M | -12.88M |
Balance Sheet | ||||||
| Total Assets | 5.85M | 4.49M | 3.82M | 2.88M | 8.08M | 9.31M |
| Cash, Cash Equivalents and Short-Term Investments | 1.32M | 956.72K | 1.17M | 530.54K | 1.65M | 2.98M |
| Total Debt | 21.74M | 19.57M | 20.05M | 17.65M | 15.14M | 13.37M |
| Total Liabilities | 45.11M | 39.23M | 31.18M | 24.67M | 20.06M | 16.06M |
| Stockholders Equity | -39.26M | -34.75M | -27.36M | -21.80M | -11.98M | -6.76M |
Cash Flow | ||||||
| Free Cash Flow | -582.33K | -1.31M | 635.28K | -804.80K | -1.31M | -9.88M |
| Operating Cash Flow | 268.56K | -706.52K | 850.70K | -419.20K | -1.11M | -9.88M |
| Investing Cash Flow | -850.89K | -602.58K | -215.42K | -385.60K | -198.43K | 666.47K |
| Financing Cash Flow | 291.38K | 1.10M | 0.00 | -309.85K | -20.78K | 12.15M |
Regenerative Medical Technology Group Technical Analysis
Positive
0.10
Price Trends
0.07
Positive
0.05
Positive
0.05
Positive
Market Momentum
<0.01
Positive
50.78
Neutral
22.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RMTG, the sentiment is Positive. The current price of 0.1 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.07, and above the 200-day MA of 0.05, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 50.78 is Neutral, neither overbought nor oversold. The STOCH value of 22.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RMTG.
Regenerative Medical Technology Group Risk Analysis
Regenerative Medical Technology Group disclosed 37 risk factors in its most recent earnings report. Regenerative Medical Technology Group reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Regenerative Medical Technology Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $1.10M | -0.11 | 27.29% | ― | 94.32% | -158.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $3.72M | -0.07 | -125.01% | ― | ― | 93.91% | |
43 Neutral | $2.47M | -0.03 | -47.41% | ― | 13.76% | 99.18% | |
43 Neutral | $9.38M | -0.01 | -18.55% | ― | ― | ― |
* Healthcare Sector Average
RMTG
Regenerative Medical Technology Group
0.08
<0.01
9.59%
BBLG
Bone Biologics
0.57
-1.58
-73.58%
IVF
INVO Fertility
0.99
-39.42
-97.56%
BJDX
Bluejay Diagnostics
0.83
-4.85
-85.35%
NIVF
NewGenIvf Group
1.14
-984.36
-99.88%
WOK
WORK Medical Technology Group LTD
2.10
-782,497.90
-100.00%
Regenerative Medical Technology Group Corporate Events
Business Operations and StrategyDelistings and Listing ChangesFinancial DisclosuresShareholder Meetings
Regenerative Medical Technology Group Highlights Growth, Financing Strategy
Positive
Aug 25, 2026
On August 20, 2026, Regenerative Medical Technology Group held a previously announced investor video call in which management addressed shareholder questions about growth, financing, and strategic direction. Executives highlighted strong revenue m...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.